ETON: Eton Pharmaceuticals Forvard P/E multiplikatori

etonpharma.com (ETON) grafik logotipi

GURU.Markets platformasidagi Eton Pharmaceuticals (ETON) bozor dinamikasi, u yerda P/E koeffitsiyenti 22.20 ni tashkil etadi, ushbu kamyob patologiyalar uchun dori vositalarini ishlab chiquvchi kompaniyaning faoliyatini aks ettiradi. Shifokorlar va bemorlar oilalari orasidagi yuqori e'tirof ergonomik terapevtik shakllarning yaratilishi bilan bog'liq. Top-menejmentning samaradorligi nisha mahsulotlarning bozorga tezkor ravishda chiqarilishi va FDA tomonidan muntazam ravishda tartibga soluvchi tasdiqlari bilan isbotlangan.

etonpharma.com - ETON Narxning kutilayotgan foydaga nisbati (davr: 04.07.2022 - 17.11.2026)

Eton Pharmaceuticals, Inc. (ETON) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Fundamental baholash:ETON Eton Pharmaceuticals, Inc.
etonpharma.com brendining mahsuloti

Investitsiya risklarini minimallashtirish uchun aktivning joriy bozor qiymatini uning potentsial daromadi bilan solishtirish zarur. Ushbu metrika bozor kapitalizatsiyasining kutilayotgan foydaga nisbati sifatida hisoblanadi va kelajakdagi pul oqimlariga bo'lgan bozor kutuvlarini aks ettiradi. Kompaniyaning forward P/E koeffitsiyentini tahlil qilish orqali investor biznesning haddan tashqari qimmat baholanganlik darajasini aniqlaydi. Eton Pharmaceuticals (ETON) uchun ushbu ko'rsatkich juda muhimdir, chunki foyda bevosita shartnomaviy ishlab chiqarish tashkilotlarining (CMO) ishonchliligiga bog'liq. Autsorsing samaradorligi patentlarning real qiymatini belgilaydi.

Eton Pharmaceuticals raqobatchilari tahlili

Kelajakdagi narxning foydaga nisbati Vertex Pharmaceuticals Inc. (VRTX)|Kelajakdagi narxning foydaga nisbati ALNY (Alnylam Inc.)|Forvard P/E multiplikatori INSM (insmed.com)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati United Therapeutics Corporation (UTHR)|BMRN: Prognoz qilingan narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati BBIO|BGM: Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Cogent Bio (COGT)|XERS (Xeris Biopharma Holdings) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati KROS (Keros Therapeutics, Inc.)|Prognoz qilingan narxning foydaga nisbati ARCT (Arcturus Therapeutics Holdings Inc.)|KMDA (Kamada Ltd) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Fulcrum Therapeutics, Inc. FULC|ABEO (Abeona) - Narxning kutilayotgan foydaga nisbati|Mereo BioPharma Group plc - Forvard P/E multiplikatori|PLX - Forvard P/E multiplikatori|PLRX: Forvard P/E multiplikatori|Applied Therapeutics Inc. (APLT) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Rein Therapeutics, Inc.|GELS: Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Aytu BioPharma Inc (AYTU)|Prognoz qilingan narxning foydaga nisbati Chemomab Therapeutics Ltd. CMMB|Forvard P/E multiplikatori SRXH (SRx Health Solutions Inc)|Forvard P/E multiplikatori Polyrizon Ltd PLRZ|Aeterna Zentaris - Forvard P/E multiplikatori|Cyclo Therapeutics (CYTH) - Prognoz qilingan narxning foydaga nisbati|Inozyme Pharma, Inc. (INZY) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narx-foyda nisbati reneopharma.com (RPHM)|Kelajakdagi narxning foydaga nisbati COSCIENS Biopharma Inc